FFO (TTM)

FFO/share (TTM)

FFO (Quarter)

FFO/share (Quarter)

Price per share at the end of the period divided by the last reported earnings

Price/FFO

Size (ft²)

Occupancy

Alexander’s, Inc. is a real estate investment trust (REIT) engaged in leasing, managing, developing and redeveloping properties. Alexander’s activities are conducted through its manager, Vornado Realty Trust. Alexander’s has seven properties in the greater New York City metropolitan area consisting of: 731 Lexington Avenue office and retail (including Bloomberg, L.P.'s world headquarters), the Rego Center complex in Rego Park, Queens, including the Rego Park I, II, and III retail properties and The Alexander apartment tower, and retail properties located in Paramus, NJ & Flushing, NY.

Alexander's Inc

The main earnings metric reported by the REIT

If the REIT is managed by an internal (employees) or external (separate company) team

Period: 2023 Q2

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2023 Q3

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2023 Q4

Years since IPO: 15/15,
FFO Growth: 3/15,
FFO/share Growth: 3/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2024 Q1

Years since IPO: 15/15,
FFO Growth: 15/15,
FFO/share Growth: 20/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2024 Q2

Years since IPO: 15/15,
FFO Growth: 15/15,
FFO/share Growth: 20/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2024 Q3

Years since IPO: 15/15,
FFO Growth: 15/15,
FFO/share Growth: 20/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2024 Q4

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2025 Q1

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2025 Q2

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2025 Q3

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2025 Q4

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

Period: 2026 Q1

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 0/15,
Debt: 0/15
            

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's FFO

FFO Growth

Assessment of recent increases in FFO per share, indicating profitability

FFO/share Growth

Analysis of the recent Dividend track record

Dividend Growth

Payout level to determine if the dividend is safe

Payout Ratio

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

Stock News Discount chains gain share: Budget-conscious consumers are flocking to discounters, with Aldi adding 17 million U.S. customers in 2025 and planning 1

First Look: Aramco profit jump, Nvidia-Corning deal, GM fined

ALX Oncology NASDAQ: ALXO executives used the company's first-quarter 2026 earnings call to highlight new clinical data for its lead CD47 blocker, evorpacept, and to provide updates on its EGFR-targeted antibody-drug conjugate program, ALX2004. CEO Jason Lettmann said the quarter featured “continued good execution,” including a February financing and the addition of Jeff Knight as chief development and chief operating officer.

ALX Oncology Q1 Earnings Call Highlights

- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this combination -

ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

- Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept -

ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression

On May 01, 2026, Alexander's Inc (ALX) shares fell 3.0%, closing at $244.34. The stock has traded within a 52-week range of $201.28 to $260.84, reflecting some

A Look at Alexander's Inc (ALX) After 3.0% Decline -- GF Value $203.84 vs Price $244.34

- Company Will Discuss Data and Report First Quarter 2026 Financial Results on May 8 - SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that new data from the Phase 1b/2 clinical trial evaluating the company's investigational CD47-inhibitor evorpacept in combination with Jazz Pharmaceuticals' zanidatamab (ZIIHERA®) in heavily pretreated patients with HER2-positive metastatic breast cancer (mBC) will be presented at the ESMO Breast Cancer 2026 Congress in Berlin on May 7.

ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026

PARAMUS, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable on May 29, 2026 to stockholders of record on May 11, 2026.

Alexander's Declares Quarterly $4.50 Dividend on Common Shares

PARAMUS, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it will file its quarterly report on Form 10-Q for the quarter ended March 31, 2026 with the U.S. Securities and Exchange Commission and issue its first quarter earnings release on Monday, May  4, 2026, before the New York Stock Exchange opens.

Alexander's Announces First Quarter Earnings Release Date and Vornado Realty Trust Quarterly Conference Call

SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, announced that the Compensation Committee of the Board of Directors of ALX Oncology approved the granting of an inducement stock option to purchase a total of 800,000 shares of ALX Oncology's common stock to Jeff Knight, M.P.H., Chief Development and Operating Officer, on April 16, 2026 in connection with the commencement of his employment. Mr. Knight's inducement stock option is subject to the terms of the ALX Oncology Holdings Inc. 2025 Inducement Equity Incentive Plan and related forms of agreements, and was granted as an inducement material to Mr. Knight to enter into employment with ALX Oncology in accordance with Nasdaq Listing Rule 5635(c)(4).

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

- Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution

ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer

Alexander's (NYSE: ALX - Get Free Report) and Four Corners Property Trust (NYSE: FCPT - Get Free Report) are both finance companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability. Volatility and Risk Alexander's has a beta

Alexander’s (NYSE:ALX) vs. Four Corners Property Trust (NYSE:FCPT) Critical Analysis

SG Americas Securities LLC grew its stake in Alexander's, Inc. (NYSE: ALX) by 962.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,952 shares of the real estate investment trust's stock after acquiring an additional 9,921 shares during

SG Americas Securities LLC Has $2.39 Million Position in Alexander’s, Inc. $ALX

Alexander's, Inc. (NYSE: ALX - Get Free Report) shares crossed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $230.09 and traded as high as $251.00. Alexander's shares last traded at $244.4490, with a volume of 69,183 shares changing hands. Analyst Ratings Changes A number of analysts

Alexander’s (NYSE:ALX) Shares Pass Above 200 Day Moving Average   – Should You Sell?

- DATA FROM PHASE 1B/2 TRIAL OF EVORPACEPT + ZANIDATAMAB PRESENTED AT ESMO BREAST CANCER 2026 SHOWED ALL PATIENTS WITH CONFIRMED HER2-POSITIVE DISEASE AND HIGH CD47 EXPRESSION EXPERIENCED DURABLE RESPONSES TO THIS COMBINATION -

ALX ONCOLOGY REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

- DATA FROM PHASE 1B/2 TRIAL PRESENTED AT ESMO BREAST CANCER 2026 FURTHER VALIDATE A BIOMARKER-DRIVEN DEVELOPMENT STRATEGY FOR EVORPACEPT -

ALX ONCOLOGY'S EVORPACEPT IN COMBINATION WITH ZANIDATAMAB GENERATES PROMISING, DURABLE RESPONSE IN PATIENTS WITH ADVANCED HER2-POSITIVE BREAST CANCER AND HIGH CD47 EXPRESSION

- COMPANY WILL DISCUSS DATA AND REPORT FIRST QUARTER 2026 FINANCIAL RESULTS ON MAY 8 - SOUTH SAN FRANCISCO, CALIF., APRIL 30, 2026 (GLOBE NEWSWIRE) -- ALX ONCOLOGY HOLDINGS INC. ("ALX ONCOLOGY"; NASDAQ: ALXO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING A PIPELINE OF NOVEL THERAPIES DESIGNED TO TREAT CANCER AND EXTEND PATIENTS' LIVES, TODAY ANNOUNCED THAT NEW DATA FROM THE PHASE 1B/2 CLINICAL TRIAL EVALUATING THE COMPANY'S INVESTIGATIONAL CD47-INHIBITOR EVORPACEPT IN COMBINATION WITH JAZZ PHARMACEUTICALS' ZANIDATAMAB (ZIIHERA) IN HEAVILY PRETREATED PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER (MBC) WILL BE PRESENTED AT THE ESMO BREAST CANCER 2026 CONGRESS IN BERLIN ON MAY 7.

ALX ONCOLOGY ANNOUNCES THAT CD47 BIOMARKER DATA FROM CLINICAL TRIAL EVALUATING EVORPACEPT + ZANIDATAMAB COMBINATION IN ADVANCED BREAST CANCER WILL BE PRESENTED AT ESMO BREAST CANCER 2026

PARAMUS, N.J., APRIL 29, 2026 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (NYSE: ALX) TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS DECLARED A REGULAR QUARTERLY DIVIDEND OF $4.50 PER SHARE PAYABLE ON MAY 29, 2026 TO STOCKHOLDERS OF RECORD ON MAY 11, 2026.

ALEXANDER'S DECLARES QUARTERLY $4.50 DIVIDEND ON COMMON SHARES

PARAMUS, N.J., APRIL 21, 2026 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (NYSE: ALX) TODAY ANNOUNCED THAT IT WILL FILE ITS QUARTERLY REPORT ON FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 2026 WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION AND ISSUE ITS FIRST QUARTER EARNINGS RELEASE ON MONDAY, MAY 4, 2026, BEFORE THE NEW YORK STOCK EXCHANGE OPENS.

ALEXANDER'S ANNOUNCES FIRST QUARTER EARNINGS RELEASE DATE AND VORNADO REALTY TRUST QUARTERLY CONFERENCE CALL

SOUTH SAN FRANCISCO, CALIF., APRIL 17, 2026 (GLOBE NEWSWIRE) -- ALX ONCOLOGY HOLDINGS INC. (ALX ONCOLOGY, NASDAQ: ALXO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING A PIPELINE OF NOVEL THERAPIES DESIGNED TO TREAT CANCER AND EXTEND PATIENTS' LIVES, ANNOUNCED THAT THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS OF ALX ONCOLOGY APPROVED THE GRANTING OF AN INDUCEMENT STOCK OPTION TO PURCHASE A TOTAL OF 800,000 SHARES OF ALX ONCOLOGY'S COMMON STOCK TO JEFF KNIGHT, M.P.H., CHIEF DEVELOPMENT AND OPERATING OFFICER, ON APRIL 16, 2026 IN CONNECTION WITH THE COMMENCEMENT OF HIS EMPLOYMENT. MR. KNIGHT'S INDUCEMENT STOCK OPTION IS SUBJECT TO THE TERMS OF THE ALX ONCOLOGY HOLDINGS INC. 2025 INDUCEMENT EQUITY INCENTIVE PLAN AND RELATED FORMS OF AGREEMENTS, AND WAS GRANTED AS AN INDUCEMENT MATERIAL TO MR. KNIGHT TO ENTER INTO EMPLOYMENT WITH ALX ONCOLOGY IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

ALX ONCOLOGY REPORTS INDUCEMENT GRANT AS PERMITTED BY THE NASDAQ LISTING RULES

- VETERAN BIOPHARMACEUTICAL AND ONCOLOGY LEADER BRINGS MORE THAN THREE DECADES OF EXPERIENCE ACROSS CLINICAL DEVELOPMENT, REGULATORY, AND OPERATIONAL EXECUTION

ALX ONCOLOGY APPOINTS JEFF KNIGHT AS CHIEF DEVELOPMENT AND OPERATING OFFICER

PARAMUS, N.J., MARCH 09, 2026 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (NYSE: ALX) ANNOUNCED TODAY THAT IT HAS ENTERED INTO AN AGREEMENT TO SELL ITS REGO PARK I PROPERTY TO NORTHWELL HEALTH, INC. THE GROSS PURCHASE PRICE IS $235.5 MILLION AND THE NET PROCEEDS WILL BE $202 MILLION. THE PROPERTY IS UNENCUMBERED.

ALEXANDER'S TO SELL REGO PARK I FOR NET PROCEEDS OF $202 MILLION

- CLINICAL DEVELOPMENT FOR BOTH THE INVESTIGATIONAL CD47-INHIBITOR EVORPACEPT AND THE NOVEL EGFR-TARGETED ANTIBODY-DRUG CONJUGATE ALX2004 REMAINS ON TRACK FOLLOWING STRONG 2025 EXECUTION; COMPANY ANTICIPATES MULTIPLE MEANINGFUL DATA SETS AND MILESTONES IN THE COMING 12 TO 18 MONTHS - - EVORPACEPT BIOMARKER STRATEGY VALIDATED BY DATA FROM BOTH THE PHASE 2 ASPEN-06 GASTRIC CANCER TRIAL AND THE PHASE 1B/2 BREAST CANCER TRIAL, INDEPENDENTLY SUGGESTING CD47 OVEREXPRESSION IS PREDICTIVE OF EVORPACEPT ACTIVITY AND DRIVES DURABLE BENEFIT IN HER2-POSITIVE CANCERS - - FULL BIOMARKER ANALYSIS FROM PHASE 1B/2 EVORPACEPT-ZANIDATAMAB COMBINATION TRIAL ACCEPTED FOR POSTER PRESENTATION AT ESMO BREAST CANCER 2026 ANNUAL CONGRESS - - PHASE 2 ASPEN-09 BREAST CANCER TRIAL IS CURRENTLY ENROLLING PATIENTS AND WILL EVALUATE EVORPACEPT EFFICACY BY CD47 EXPRESSION LEVELS, WITH TOPLINE DATA ANTICIPATED MID-2027 - - PHASE 1 TRIAL EVALUATING ALX2004 CONTINUES TO ENROLL PATIENTS IN THE THIRD DOSE COHORT; SAFETY DATA FROM DOSE-ESCALATION PHASE EXPECTED IN 2H 2026 - - COMPANY COMPLETED A $150 MILLION REGISTERED OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS, EXTENDING CASH RUNWAY THROUGH 1H 2028 INCLUSIVE OF KEY CLINICAL PROGRAM MILESTONES FOR EVORPACEPT AND ALX2004 - - BARBARA KLENCKE, M.D., APPOINTED TO CHIEF MEDICAL OFFICER ON A PERMANENT BASIS - - COMPANY TO HOST WEBCAST ON FRIDAY, FEBRUARY 27, AT 5:30 A.M.

ALX ONCOLOGY REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS ANDPROVIDES CORPORATE UPDATE

SOUTH SAN FRANCISCO, CALIF., FEB. 19, 2026 (GLOBE NEWSWIRE) -- ALX ONCOLOGY HOLDINGS INC. ("ALX ONCOLOGY; NASDAQ: ALXO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING A PIPELINE OF NOVEL THERAPIES DESIGNED TO TREAT CANCER AND EXTEND PATIENTS' LIVES, TODAY ANNOUNCED THAT ALX ONCOLOGY LEADERSHIP WILL PARTICIPATE IN THE WELLS FARGO EXECUTIVE BIOTECH SUMMIT, TD COWEN 46TH ANNUAL HEALTH CARE CONFERENCE, AND UBS BIOTECH SUMMIT.

Alexander's Inc

ALX

Price

Dividends

Yield

Dividends

No items found.

Financial Reports

No items found.

Diversification by Property Type

No items found.

Diversification by Country

No items found.

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

ALX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Dividends

Yield

Dividends

No items found.

Financial Reports

No items found.

Diversification by Property Type

No items found.

Diversification by Country

No items found.

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

ALX